

# Natasha Woodward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7633485/publications.pdf>

Version: 2024-02-01

30  
papers

1,008  
citations

933447

10  
h-index

677142

22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 37-46.	4.4	219
2	Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. <i>Annals of Oncology</i> , 2020, 31, 1526-1535.	1.2	214
3	Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. <i>American Heart Journal</i> , 2009, 158, 294-301.	2.7	197
4	Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1504-1513.	1.2	122
5	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
6	Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 66-80.	4.4	49
7	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	2.9	24
8	Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. <i>BMC Ophthalmology</i> , 2014, 14, 18.	1.4	19
9	Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE). <i>Clinical Breast Cancer</i> , 2019, 19, 216-224.	2.4	13
10	A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1815-1825.	2.6	12
11	Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. <i>Journal of Clinical Pathology</i> , 2017, 70, 954-960.	2.0	10
12	Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1181-e1187.	2.4	10
13	Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor- $\alpha$ and progesterone receptor- $\beta$ . <i>British Journal of Cancer</i> , 2018, 119, 1316-1325.	6.4	9
14	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 3-18.	1.1	8
15	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 3-11.	1.1	4
16	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline <i>BRCA</i> mutation. <i>Journal of Clinical Oncology</i> , 2018, 36, 1069-1069.	1.6	4
17	Single institution outcomes of treatment of severe aplastic anaemia. <i>Internal Medicine Journal</i> , 2001, 31, 337-342.	0.8	3
18	Abstract P4-14-12: Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). <i>Cancer Research</i> , 2016, 76, P4-14-12-P4-14-12.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Abstract P4-21-31: Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). , 2017, , .		3
20	Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 19-31.	1.1	2
21	Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 201-208.	1.1	2
22	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2 non-amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 12-21.	1.1	1
23	The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program. European Journal of Cancer. 2018, 92, S105-S106.	2.8	1
24	Abstract OT3-1-03: An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). , 2015, , .		1
25	Management of patients treated with pertuzumab in the Australian clinical practice setting. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-15.	1.1	0
26	Development of novel biomarkers predictive of endocrine sensitivity in breast cancer. Pathology, 2020, 52, S8.	0.6	0
27	Letter to the editor: re Lu et al.. Supportive Care in Cancer, 2021, 29, 1-2.	2.2	0
28	Predicting endocrine sensitivity in breast cancer. Pathology, 2021, 53, S2.	0.6	0
29	Management of aromatase inhibitor-associated musculoskeletal symptoms: A systematic review.. Journal of Clinical Oncology, 2016, 34, 157-157.	1.6	0
30	Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germlineBRCAmutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). , 2017, , .		0